Related Experiment Video
Updated: Feb 5, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Oncolytics Biotech® Inc.: REOLYSIN® for melanoma therapy
1Oncolytics Biotech Inc., 210, 1167 Kensington Crescent NW, Calgary, AB, T2N 1X7, Canada.
Abstract:
Oncolytics Biotech® Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company's lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is in late-stage clinical testing in a range of cancers. REOLYSIN has been utilized in nearly 30 clinical trials including translational, Phase I, Phase II (single arm and randomized) and Phase III studies in a broad range of cancer indications. To date, Oncolytics has been issued more than 370 patents worldwide and has more than 230 pending applications. Issued patent claims pertaining to the reovirus cover: compositions of matter comprising reovirus; pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases and combination therapy with radiation, chemotherapy and/or immune suppressants.
Related Concept Videos
Gene Therapy
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy

